Sacubitril/valsartan - Novartis

Drug Profile

Sacubitril/valsartan - Novartis

Alternative Names: AHU-377/valsartan; Entresto; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitril

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Rovi
  • Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure
  • Phase III Essential hypertension; Hypertension; Kidney disorders

Most Recent Events

  • 11 Nov 2017 Efficacy data from clinical trial in Heart failure were presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 11 Nov 2017 Pharmacodynamics data from a preclinical trial in Heart failure presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA-2017)
  • 26 Aug 2017 Updated efficacy data from the phase III PARADIGM-HF trial in Heart failure presented at the Annual Congress of the European Society of Cardiology (ESC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top